Premixed antibiotic bone cement: an in vitro comparison of antimicrobial efficacy.
After Food and Drug Administration (FDA) approval of premixed antibiotic bone cements (polymethylmethacrylate [PMMA]), these products are being used with increasing frequency during revision and primary hip and knee arthroplasties. To date, no studies have compared the antimicrobial efficacy of more than 2 products directly. Using a 7-day modified Kirby-Bauer assay, we assessed the in vitro antibacterial properties of 5 FDA-approved, commercially available antibiotic PMMAs. Significant differences in antimicrobial activity were noted among the antibiotic PMMA products included in this investigation. Antibacterial activity of all products tested was greatest on day 1 and rapidly diminished thereafter. Results of this investigation suggest that the antibacterial efficacies of premixed antibiotic PMMA products are not equivalent.
Squire
Matthew W
MW
University of Wisconsin Department of Orthopedic Surgery, Madison, Wisconsin, USA.
Ludwig
Brian J
BJ
Thompson
Jonathan R
JR
Jagodzinski
Jason
J
Hall
Derek
D
Andes
David
D
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001419:Bacteria / Q000187:drug effects*; D001843:Bone Cements; D005839:Gentamicins / Q000008:administration & dosage; D008826:Microbial Sensitivity Tests; D019904:Polymethyl Methacrylate; D013211:Staphylococcus aureus / Q000187:drug effects; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D001843:Bone Cements; D005839:Gentamicins; D019904:Polymethyl Methacrylate; D014031:Tobramycin